04.07.2016 • NewsEvonikDevelopmentDrug Delivery

Evonik to Acquire Transferra Nanosciences

(c) Evonik
(c) Evonik

In a transaction planned to close at the end of July, Evonik will acquire the business and assets of Canadian biotechnology specialist Transferra Nanosciences, formerly known as Northern Lipids. The German chemical producer said the acquisition is “a systematic step” in the ongoing implementation growth plans for its Health Care business line and will strengthen its position in the area of parenteral drug delivery technologies and services.

A Contract Development and Manufacturing Organization (CDMO, Transferra provides services as well as products to biotechnology companies engaged in the development of pharmaceutical products, using its expertise in liposomal drug delivery systems.

The Canadian company’s services include prototype identification; scale-up and process development; analytical support and qualification of methods, as well as production of test articles for toxicology studies and cGMP manufacturing of clinical trial materials. Transferra also offers a range of extruders for large scale manufacture of commercial drug products.   

Evonik said its HealthCare arm has recently developed into a leading provider of formulation development and GMP manufacturing services to the pharmaceutical industry for advanced parenteral drug depot formulations, building on the acquisition of the Resomer portfolio of bioresorbable polymers and Surmodics Pharmaceuticals in Birmingham, Alabama, USA.  
 
The combined drug delivery businesses of the German and Canadian companies will be able to provide “a full array” of services, ranging from prototype identification to commercial manufacturing,” said Jean-Luc Herbeaux, head of Evonik Health Care.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.